Search

Your search keyword '"Pérez-Encinas, Manuel"' showing total 300 results
Start Over Author "Pérez-Encinas, Manuel"
300 results on '"Pérez-Encinas, Manuel"'

1. Impact of somatic gene mutations on the risk of thrombosis in myelofibrosis

Author

Pastor-Galán, Irene, Pereira, Arturo, Arellano-Rodrigo, Eduardo, Martín, Iván, Mosquera-Orgueira, Adrián, Gómez-Casares, María-Teresa, Hernández-Sánchez, Alberto, Ferrer-Marín, Francisca, Mora, Elvira, Velez, Patricia, Ayala, Rosa, Angona, Anna, de las Heras, Natalia, Magro, Elena, Mata-Vázquez, María-Isabel, Fox, María-Laura, González de Villambrosía, Sonia, Ramírez, María-José, García, Ana, García-Gutiérrez, Valentín, Cáceres, Amparo, Durán, María-Antonia, Senín, María-Alicia, Raya, José-María, González, José Antonio, Cuevas, Beatriz, Xicoy, Blanca, Garrote, Marta, Ferrer, Blanca, Pérez-Encinas, Manuel, Hernández-Rivas, Jesús María, Bellosillo, Beatriz, Álvarez-Larrán, Alberto, and Hernández-Boluda, Juan Carlos

Published
2024
Full Text
View/download PDF

3. CNL and aCML should be considered as a single entity based on molecular profiles and outcomes

Author

Carreño-Tarragona, Gonzalo, Álvarez-Larrán, Alberto, Harrison, Claire, Martínez-Ávila, José Carlos, Hernández-Boluda, Juan Carlos, Ferrer-Marín, Francisca, Radia, Deepti H., Mora, Elvira, Francis, Sebastian, González-Martínez, Teresa, Goddard, Kathryn, Pérez-Encinas, Manuel, Narayanan, Srinivasan, Raya, José María, Singh, Vikram, Gutiérrez, Xabier, Toth, Peter, Amat-Martínez, Paula, Mcilwaine, Louisa, Alobaidi, Magda, Mayani, Karan, McGregor, Andrew, Stuckey, Ruth, Psaila, Bethan, Segura, Adrián, Alvares, Caroline, Davidson, Kerri, Osorio, Santiago, Cutting, Robert, Sweeney, Caroline P., Rufián, Laura, Moreno, Laura, Cuenca, Isabel, Smith, Jeffery, Morales, María Luz, Gil-Manso, Rodrigo, Koutsavlis, Ioannis, Wang, Lihui, Mead, Adam J., Rozman, María, Martínez-López, Joaquín, Ayala, Rosa, and Cross, Nicholas C. P.

Published
2023
Full Text
View/download PDF

4. Low-risk polycythemia vera treated with phlebotomies: clinical characteristics, hematologic control and complications in 453 patients from the Spanish Registry of Polycythemia Vera

Author

Triguero, Ana, Pedraza, Alexandra, Pérez-Encinas, Manuel, Mata-Vázquez, María Isabel, Vélez, Patricia, Fox, Laura, Gómez-Calafat, Montse, García-Delgado, Regina, Gasior, Mercedes, Ferrer-Marín, Francisca, García-Gutiérrez, Valentín, Angona, Anna, Gómez-Casares, María Teresa, Cuevas, Beatriz, Martínez, Clara, Pérez, Raúl, Raya, José María, Guerrero, Lucía, Murillo, Ilda, Bellosillo, Beatriz, Hernández-Boluda, Juan Carlos, Sanz, Cristina, and Álvarez-Larrán, Alberto

Published
2022
Full Text
View/download PDF

5. Survival prediction and treatment optimization of multiple myeloma patients using machine-learning models based on clinical and gene expression data

Author

Mosquera Orgueira, Adrián, González Pérez, Marta Sonia, Díaz Arias, José Ángel, Antelo Rodríguez, Beatriz, Alonso Vence, Natalia, Bendaña López, Ángeles, Abuín Blanco, Aitor, Bao Pérez, Laura, Peleteiro Raíndo, Andrés, Cid López, Miguel, Pérez Encinas, Manuel Mateo, Bello López, José Luis, and Mateos Manteca, Maria Victoria

Published
2021
Full Text
View/download PDF

6. Evolving treatment patterns and outcomes in older patients (≥60 years) with AML: changing everything to change nothing?

Author

Martínez-Cuadrón, David, Serrano, Josefina, Gil, Cristina, Tormo, Mar, Martínez-Sánchez, Pilar, Pérez-Simón, José A., García-Boyero, Raimundo, Rodríguez-Medina, Carlos, López-Pavía, María, Benavente, Celina, Bergua, Juan, Lavilla-Rubira, Esperanza, Amigo, María L., Herrera, Pilar, Alonso-Domínguez, Juan M., Bernal, Teresa, Colorado, Mercedes, Sayas, María J., Algarra, Lorenzo, Vidriales, María B., Rodríguez-Macías, Gabriela, Vives, Susana, Pérez-Encinas, Manuel M., López, Aurelio, Noriega, Víctor, García-Fortes, María, Ramos, Fernando, Rodríguez-Gutiérrez, Juan I., Costilla-Barriga, Lisette, Labrador, Jorge, Boluda, Blanca, Rodríguez-Veiga, Rebeca, Martínez-López, Joaquín, Sanz, Miguel A., and Montesinos, Pau

Published
2021
Full Text
View/download PDF

7. Outcomes after intensive chemotherapy for secondary and myeloid-related changes acute myeloid leukemia patients aged 60 to 75 years old: a retrospective analysis from the PETHEMA registry

Author

Instituto de Salud Carlos III, European Commission, Pérez-Simón, José A. [0000-0003-3616-6101], Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72], Martínez-Cuadrón, David, Megías-Vericat, Juan E., Gil, Cristina, Bernal, Teresa, Tormo, Mar, Martínez-Sánchez, Pilar, Rodríguez-Medina, Carlos, Serrano, Josefina, Herrera, Pilar, Pérez-Simón, José A., Sayas, María-José, Bergua, Juan, Lavilla, Esperanza, Amigo, María Luz, Benavente, Celina, López-Lorenzo, José L., Pérez-Encinas, Manuel, Vidriales, Maria Belén, Colorado, Mercedes, Rueda, Beatriz de, García-Boyero, Raimundo, Marini, Sandra, García-Suárez, Julio, López-Pavía, María, Gómez-Roncero, María Isabel, Noriega, Víctor, López, Aurelio, Labrador, Jorge, Cabello, Ana, Sossa, Claudia, Algarra, Lorenzo, Stevenazzi, Mariana, Solana-Altabella, Antonio, Boluda, Blanca, Montesinos, Pau, Instituto de Salud Carlos III, European Commission, Pérez-Simón, José A. [0000-0003-3616-6101], Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72], Martínez-Cuadrón, David, Megías-Vericat, Juan E., Gil, Cristina, Bernal, Teresa, Tormo, Mar, Martínez-Sánchez, Pilar, Rodríguez-Medina, Carlos, Serrano, Josefina, Herrera, Pilar, Pérez-Simón, José A., Sayas, María-José, Bergua, Juan, Lavilla, Esperanza, Amigo, María Luz, Benavente, Celina, López-Lorenzo, José L., Pérez-Encinas, Manuel, Vidriales, Maria Belén, Colorado, Mercedes, Rueda, Beatriz de, García-Boyero, Raimundo, Marini, Sandra, García-Suárez, Julio, López-Pavía, María, Gómez-Roncero, María Isabel, Noriega, Víctor, López, Aurelio, Labrador, Jorge, Cabello, Ana, Sossa, Claudia, Algarra, Lorenzo, Stevenazzi, Mariana, Solana-Altabella, Antonio, Boluda, Blanca, and Montesinos, Pau

Abstract

Treatment options for patients with secondary acute myeloid leukemia (sAML) and AML with myeloid-related changes (AMLMRC) aged 60 to 75 years are scarce and unsuitable. A pivotal trial showed that CPX-351 improved complete remission with/without incomplete recovery (CR/CRi) and overall survival (OS) as compared with standard "3+7" regimens. We retrospectively analyze outcomes of 765 patients with sAML and AML-MRC aged 60 to 75 years treated with intensive chemotherapy, reported to the PETHEMA registry before CPX-351 became available. The CR/CRi rate was 48%, median OS was 7.6 months (95% confidence interval [CI]: 6.7-8.5) and event-free survival (EFS) 2.7 months (95% CI: 2-3.3), without differences between intensive chemotherapy regimens and AML type. Multivariate analyses identified age ≥70 years, Eastern Cooperative Oncology Group performance status ≥1 as independent adverse prognostic factors for CR/CRi and OS, while favorable/intermediate cytogenetic risk and NPM1 were favorable prognostic factors. Patients receiving allogeneic stem cell transplant (HSCT), autologous HSCT, and those who completed more consolidation cycles showed improved OS. This large study suggests that classical intensive chemotherapy could lead to similar CR/CRi rates with slightly shorter median OS than CPX-351.

Published
2024

8. Predicting Survival after Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: Performance of the Myelofibrosis Transplant Scoring System (MTSS) and Development of a New Prognostic Model

Author

Hernández-Boluda, Juan-Carlos, Pereira, Arturo, Alvarez-Larran, Alberto, Martín, Ana-Africa, Benzaquen, Ana, Aguirre, Lourdes, Mora, Elvira, González, Pedro, Mora, Jorge, Dorado, Nieves, Sampol, Antonia, García-Gutiérrez, Valentín, López-Godino, Oriana, Fox, María-Laura, Reguera, Juan Luis, Pérez-Encinas, Manuel, Pascual, María-Jesús, Xicoy, Blanca, Parody, Rocío, González-Pinedo, Leslie, Español, Ignacio, Avendaño, Alejandro, Correa, Juan-Gonzalo, Vallejo, Carlos, Jurado, Manuel, García-Cadenas, Irene, Osorio, Santiago, Durán, María-Antonia, Sánchez-Guijo, Fermín, Cervantes, Francisco, and Piñana, José-Luis

Published
2020
Full Text
View/download PDF

9. DNMT3A/TET2/ASXL1 Mutations are an Age-independent Thrombotic Risk Factor in Polycythemia Vera Patients: An Observational Study.

Author

Segura-Díaz, Adrián, Stuckey, Ruth, Florido, Yanira, Sobas, Marta, Álvarez-Larrán, Alberto, Ferrer-Marín, Francisca, Pérez-Encinas, Manuel, Carreño-Tarragona, Gonzalo, Fox, María L., Tazón Vega, Barbara, Cuevas, Beatriz, López Rodríguez, Juan F., Sánchez-Farías, Nuria, González-Martín, Jesús M., Gómez-Casares, María T., and Bilbao-Sieyro, Cristina

Published
2024
Full Text
View/download PDF

10. Integrating AIPSS‐MF and molecular predictors: A comparative analysis of prognostic models for myelofibrosis.

Author

Mosquera‐Orgueira, Adrián, Arellano‐Rodrigo, Eduardo, Garrote, Marta, Martín, Iván, Pérez‐Encinas, Manuel, Gómez‐Casares, María‐Teresa, Hernández‐Sánchez, Alberto, Ferrer‐Marín, Francisca, Mora, Elvira, Velez, Patricia, Ayala, Rosa, Angona, Anna, Heras, Natalia de las, Magro, Elena, Pérez‐Míguez, Carlos, Crucitti, Davide, Mata‐Vázquez, María‐Isabel, Fox, María‐Laura, González de Villambrosía, Sonia, and Ramírez, María‐José

Published
2024
Full Text
View/download PDF

11. Corrigendum: Evaluation of the Stellae-123 prognostic gene expression signature in acute myeloid leukemia

Author

Mosquera Orgueira, Adrián, primary, Peleteiro Raíndo, Andrés, additional, Díaz Arias, José Ángel, additional, Antelo Rodríguez, Beatriz, additional, López Riñón, Mónica, additional, Cerchione, Claudio, additional, de la Fuente Burguera, Adolfo, additional, González Pérez, Marta Sonia, additional, Martinelli, Giovanni, additional, Montesinos Fernández, Pau, additional, and Pérez Encinas, Manuel Mateo, additional

Published
2023
Full Text
View/download PDF

12. DNMT3A/TET2/ASXL1 mutations are an age-independent thrombotic risk factor in polycythemia vera patients: an observational study

Author

Segura-Díaz, Adrián, primary, Stuckey, Ruth, additional, Florido, Yanira, additional, Sobas, Marta, additional, Álvarez-Larrán, Alberto, additional, Ferrer-Marín, Francisca, additional, Pérez-Encinas, Manuel, additional, Carreño-Tarragona, Gonzalo, additional, Fox, María Laura, additional, Vega, Barbara Tazón, additional, Cuevas, Beatriz, additional, Rodríguez, Juan Francisco López, additional, Farías-Sánchez, Nuria, additional, González-Martín, Jesús M., additional, Gómez-Casares, María Teresa, additional, and Bilbao-Sieyro, Cristina, additional

Published
2023
Full Text
View/download PDF

13. Presence of Myeloid Mutations in Patients with Chronic Myeloid Leukemia Increases Risk of Cardiovascular Event on Tyrosine Kinase Inhibitor Treatment

Author

Stuckey, Ruth, primary, Segura-Díaz, Adrián, additional, Sáez Perdomo, María Nieves, additional, Pérez Encinas, Manuel Mateo, additional, González San Miguel, Jóse David, additional, Florido, Yanira, additional, Sánchez-Sosa, Santiago, additional, López-Rodríguez, Juan Francisco, additional, Bilbao-Sieyro, Cristina, additional, and Gómez-Casares, María Teresa, additional

Published
2023
Full Text
View/download PDF

14. Improved personalized survival prediction of patients with diffuse large B-cell Lymphoma using gene expression profiling

Author

Mosquera Orgueira, Adrián, Díaz Arias, José Ángel, Cid López, Miguel, Peleteiro Raíndo, Andrés, Antelo Rodríguez, Beatriz, Aliste Santos, Carlos, Alonso Vence, Natalia, Bendaña López, Ángeles, Abuín Blanco, Aitor, Bao Pérez, Laura, González Pérez, Marta Sonia, Pérez Encinas, Manuel Mateo, Fraga Rodríguez, Máximo Francisco, and Bello López, José Luis

Published
2020
Full Text
View/download PDF

15. Prognostic risk models for transplant decision-making in myelofibrosis

Author

Hernández-Boluda, Juan-Carlos, Pereira, Arturo, Correa, Juan-Gonzalo, Alvarez-Larrán, Alberto, Ferrer-Marín, Francisca, Raya, José-María, Martínez-López, Joaquín, Velez, Patricia, Pérez-Encinas, Manuel, Estrada, Natalia, García-Gutiérrez, Valentín, Fox, María-Laura, Payer, Angel, Kerguelen, Ana, Cuevas, Beatriz, Durán, María-Antonia, Ramírez, María-José, Gómez-Casares, María-Teresa, Mata-Vázquez, María-Isabel, Mora, Elvira, Gómez, Montse, and Cervantes, Francisco

Published
2018
Full Text
View/download PDF

16. Clinical outcomes after CPX ‐351 in patients with high‐risk acute myeloid leukemia: A comparison with a matched cohort from the Spanish PETHEMA registry

Author

Bernal, Teresa, primary, Moreno, Ainhoa Fernández, additional, de LaIglesia, Almudena, additional, Benavente, Celina, additional, García‐Noblejas, Ana, additional, Belmonte, Daniel García, additional, Riaza, Rosalía, additional, Salamero, Olga, additional, Foncillas, Maria Angeles, additional, Roldán, Alicia, additional, Concepción, Víctor Noriega, additional, González, Laura Llorente, additional, Bergua Burgués, Juan Miguel, additional, Lorente de Uña, Soraya, additional, Rodríguez‐Macías, Gabriela, additional, de la Fuente Burguera, Adolfo, additional, García Pérez, Maria José, additional, López‐Lorenzo, Jose Luis, additional, Martínez, Pilar, additional, Aláez, Concepción, additional, Callejas, Marta, additional, Martínez‐Chamorro, Carmen, additional, Roca, José Rifón, additional, Barciela, Lourdes Amador, additional, Mena Durán, Armando V., additional, Gómez Correcha, Karoll, additional, Lavilla Rubira, Esperanza, additional, Amigo, María Luz, additional, Vall‐llovera, Ferran, additional, Garrido, Ana, additional, García‐Fortes, María, additional, de Miguel Llorente, Dunia, additional, Leonardo, Anastasia Aules, additional, Cervero, Carlos, additional, Jordá, Rosa Coll, additional, Pérez‐Encinas, Manuel M., additional, Zarzuela, Marta Polo, additional, Figuera, Angela, additional, Rad, Guillermo, additional, Martínez‐Cuadrón, David, additional, and Montesinos, Pau, additional

Published
2023
Full Text
View/download PDF

17. Outcomes after intensive chemotherapy for secondary and myeloidrelated changes acute myeloid leukemia patients aged 60 to 75 years old: a retrospective analysis from the PETHEMA registry

Author

Martínez-Cuadrón, David, primary, Megías-Vericat, Juan E., additional, Gil, Cristina, additional, Bernal, Teresa, additional, Tormo, Mar, additional, Martínez-Sánchez, Pilar, additional, Rodríguez-Medina, Carlos, additional, Serrano, Josefina, additional, Herrera, Pilar, additional, Simón, José A. Pérez, additional, Sayas, María J., additional, Bergua, Juan, additional, Lavilla-Rubira, Esperanza, additional, Amigo, Maria Luz, additional, Benavente, Celina, additional, Lorenzo, Jose L. López, additional, Pérez-Encinas, Manuel M., additional, Vidriales, María B., additional, Colorado, Mercedes, additional, De Rueda, Beatriz, additional, García-Boyero, Raimundo, additional, Marini, Sandra, additional, García-Suárez, Julio, additional, López-Pavía, María, additional, Gómez-Roncero, Maria I., additional, Noriega, Víctor, additional, López, Aurelio, additional, Labrador, Jorge, additional, Cabello, Ana, additional, Sossa, Claudia, additional, Algarra, Lorenzo, additional, Stevenazzi, Mariana, additional, Solana-Altabella, Antonio, additional, Boluda, Blanca, additional, and Montesinos, Pau, additional

Published
2023
Full Text
View/download PDF

18. A prognostic model based on gene expression parameters predicts a better response to bortezomib-containing immunochemotherapy in diffuse large B-cell lymphoma

Author

Mosquera Orgueira, Adrián, Díaz Arías, Jose Ángel, Serrano Martín, Rocio, Portela Piñeiro, Victor, Cid López, Miguel, Peleteiro Raíndo, Andrés, Bao Pérez, Laura, González Pérez, Marta Sonia, Pérez Encinas, Manuel Mateo, Fraga Rodríguez, Máximo Francisco, Vallejo Llamas, Juan Carlos, and Bello López, José Luis

Subjects
Cancer Research, Oncology
Abstract

Diffuse Large B-cell Lymphoma (DLBCL) is the most common type of aggressive lymphoma. Approximately 60% of fit patients achieve curation with immunochemotherapy, but the remaining patients relapse or have refractory disease, which predicts a short survival. Traditionally, risk stratification in DLBCL has been based on scores that combine clinical variables. Other methodologies have been developed based on the identification of novel molecular features, such as mutational profiles and gene expression signatures. Recently, we developed the LymForest-25 profile, which provides a personalized survival risk prediction based on the integration of transcriptomic and clinical features using an artificial intelligence system. In the present report, we studied the relationship between the molecular variables included in LymForest-25 in the context of the data released by the REMoDL-B trial, which evaluated the addition of bortezomib to the standard treatment (R-CHOP) in the upfront setting of DLBCL. For this, we retrained the machine learning model of survival on the group of patients treated with R-CHOP (N=469) and then made survival predictions for those patients treated with bortezomib plus R-CHOP (N=459). According to these results, the RB-CHOP scheme achieved a 30% reduction in the risk of progression or death for the 50% of DLBCL patients at higher molecular risk (p-value 0.03), potentially expanding the effectiveness of this treatment to a wider patient population as compared with other previously defined risk groups.

Published
2023

20. Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase Inhibitors

Author

Pérez-Lamas, Lucía, primary, Luna, Alejandro, additional, Boque, Concepción, additional, Xicoy, Blanca, additional, Giraldo, Pilar, additional, Pérez López, Raúl, additional, Ruiz Nuño, Concepción, additional, De las Heras, Natalia, additional, Mora Casterá, Elvira, additional, López Marín, Javier, additional, Segura Díaz, Adrián, additional, Gómez, Valle, additional, Vélez Tenza, Patricia, additional, Sierra Pacho, Magdalena, additional, Vera Goñi, Juan Antonio, additional, Moreno Vega, Melania, additional, Alvarez-Larrán, Alberto, additional, Cortés, Montse, additional, Pérez Encinas, Manuel, additional, Carrascosa Mastell, Patricia, additional, Angona, Anna, additional, Rosell, Ana, additional, Lakhwani, Sunil, additional, Colorado, Mercedes, additional, Ramila, Elena, additional, Cervero, Carlos, additional, Cuevas, Beatriz, additional, Villalón Blanco, Lucía, additional, de Paz, Raquel, additional, Paz Coll, Antonio, additional, Fernández, María José, additional, Felipe Casado, Luis, additional, Alonso-Domínguez, Juan Manuel, additional, Anguita Arance, María Magdalena, additional, Salamanca Cuenca, Araceli, additional, Jiménez-Velasco, Antonio, additional, Prendes, Santiago Osorio, additional, Santaliestra, Marta, additional, Lis Chulvi, María José, additional, Hernández-Boluda, Juan Carlos, additional, and García-Gutiérrez, Valentín, additional

Published
2023
Full Text
View/download PDF

21. Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis

Author

Mosquera Orgueira, Adrián, Pérez Encinas, Manuel, Hernández Sánchez, Alberto, González Martínez, Teresa, Arellano Rodrigo, Eduardo, Martínez Elicegui, Javier, Villaverde Ramiro, Ángela, Raya, José María, Ayala, Rosa, Ferrer Marín, Francisca, Fox, María Laura, Velez, Patricia, Mora, Elvira, Xicoy, Blanca, Mata Vázquez, María Isabel, García Fortes, María, Angona, Anna, Cuevas, Beatriz, Senín, María Alicia, Ramírez Payer, Angel, Ramírez, María José, Pérez López, Raúl, González de Villambrosía, Sonia, Martínez Valverde, Clara, Gómez Casares, María Teresa, García Hernández, Carmen, Gasior, Mercedes, Bellosillo Paricio, Beatriz, Steegmann, Juan Luis, Álvarez Larrán, Alberto, Hernández Rivas, Jesús María, Hernández Boluda, Juan Carlos, The Spanish MPN Group (GEMFIN)., Institut Català de la Salut, [Mosquera-Orgueira A, Pérez-Encinas M] Hospital Clínico Universitario, Santiago de Compostela, Spain. [Hernández-Sánchez A, González-Martínez T, Martínez-Elicegui J] Hospital Clínico, Salamanca, Spain. [Arellano-Rodrigo E] Hospital Clínic, Institut d’Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain. [Fox ML] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus

Subjects
Intel·ligència artificial - Aplicacions a la medicina, Pronòstic mèdic, Mielofibrosi, Immunology, Myelofibrosis, Neoplasms::Neoplasms by Histologic Type::Leukemia::Leukemia, Myeloid::Leukemia, Myeloid, Acute [DISEASES], enfermedades hematológicas y linfáticas::enfermedades hematológicas::enfermedades de la médula ósea::trastornos mieloproliferativos [ENFERMEDADES], Cell Biology, Hematology, Prognosis, Biochemistry, Ciencias de la información::metodologías computacionales::algoritmos::inteligencia artificial::aprendizaje automático [CIENCIA DE LA INFORMACIÓN], neoplasias::neoplasias por tipo histológico::leucemia::leucemia mieloide::leucemia mieloide aguda [ENFERMEDADES], Aprenentatge automàtic, Machine learning, Sang - Malalties, Hemic and Lymphatic Diseases::Hematologic Diseases::Bone Marrow Diseases::Myeloproliferative Disorders [DISEASES], Information Science::Computing Methodologies::Algorithms::Artificial Intelligence::Machine Learning [INFORMATION SCIENCE]
Abstract

Aprendizaje automático; Mielofibrosis Aprenentatge automàtic; Mielofibrosi Machine learning; Myelofibrosis Myelofibrosis (MF) is a myeloproliferative neoplasm (MPN) with heterogeneous clinical course. Allogeneic hematopoietic cell transplantation remains the only curative therapy, but its morbidity and mortality require careful candidate selection. Therefore, accurate disease risk prognostication is critical for treatment decision-making. We obtained registry data from patients diagnosed with MF in 60 Spanish institutions (N = 1386). These were randomly divided into a training set (80%) and a test set (20%). A machine learning (ML) technique (random forest) was used to model overall survival (OS) and leukemia-free survival (LFS) in the training set, and the results were validated in the test set. We derived the AIPSS-MF (Artificial Intelligence Prognostic Scoring System for Myelofibrosis) model, which was based on 8 clinical variables at diagnosis and achieved high accuracy in predicting OS (training set c-index, 0.750; test set c-index, 0.744) and LFS (training set c-index, 0.697; test set c-index, 0.703). No improvement was obtained with the inclusion of MPN driver mutations in the model. We were unable to adequately assess the potential benefit of including adverse cytogenetics or high-risk mutations due to the lack of these data in many patients. AIPSS-MF was superior to the IPSS regardless of MF subtype and age range and outperformed the MYSEC-PM in patients with secondary MF. In conclusion, we have developed a prediction model based exclusively on clinical variables that provides individualized prognostic estimates in patients with primary and secondary MF. The use of AIPSS-MF in combination with predictive models that incorporate genetic information may improve disease risk stratification.

Published
2023

22. Thrombogenesis Mechanisms of High Doses of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) Compared to Tyrosine Kinase Inhibitors

Author

Aguila, Sonia, primary, Cuenca, Ernesto J, additional, Lys, Maria Jose, additional, Garcia-Hernandez, Carmen, additional, Fernández, Maria Jose, additional, Noya, Maria, additional, García Gutiérrez, Valentín, additional, Palomera, Luis, additional, Senín, Alicia, additional, Perez Lopez, Raul, additional, Pérez-Encinas, Manuel, additional, Angona, Anna, additional, Puerta, Jose M, additional, Vallansot, Rolando, additional, Conesa, Venancio, additional, Hernandez Boluda, Juan Carlos, additional, Rosell, Ana, additional, Cortes, Montse, additional, Ortí, Guillermo, additional, Xicoy, Blanca, additional, Carreño, Gonzalo, additional, Mora Castera, Elvira, additional, Giraldo, Pilar, additional, Lozano, Maria Luisa, additional, Casado, Luis Felipe, additional, Ferrer Marin, Francisca, additional, and Gelmc, on Behalf Of, additional

Published
2022
Full Text
View/download PDF

23. Efficacy and Safety of Treatment Venetoclax Monotherapy or Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) in the Real-World Setting in Spain: An Update of the Venares Study

Author

Ferra, Christelle, primary, Terol, María José, additional, Marquet Palomanes, Juan, additional, Ramírez Payer, Angel, additional, Moreno, Carol, additional, Osorio, Santiago, additional, De la Cruz, Fátima, additional, Garcia-Marco, Jose A., additional, Ortiz, Macarena, additional, Rios Herranz, Eduardo, additional, Magnano, Laura, additional, Iraheta, Sandra, additional, Puerta, Jose Manuel, additional, de la Serna, Javier, additional, Smucler, Alicia, additional, Arguiñano, Jose Maria, additional, Loscertales, Javier, additional, Muiña, Begoña, additional, Fernández, Rubén, additional, García, Tomas, additional, Márquez, José A., additional, Muntañola Prat, Ana, additional, Perez Persona, Ernesto, additional, Yáñez, Lucrecia, additional, Pérez-Encinas, Manuel, additional, González Díaz, Marcos, additional, Caballero, Gonzalo, additional, Andreu, María Angeles, additional, Andreu, Rafael, additional, Ruiz-Zorrilla, Ana, additional, Moreno, Diana, additional, and Baltasar, Patricia, additional

Published
2022
Full Text
View/download PDF

24. Correction: Gene expression profiling identifies FLT3 mutation-like cases in wild-type FLT3 acute myeloid leukemia

Author

Mosquera Orgueira, Adrián, primary, Peleteiro Raíndo, Andrés, additional, Cid López, Miguel, additional, Antelo Rodríguez, Beatriz, additional, Díaz Arias, José Ángel, additional, Ferreiro Ferro, Roi, additional, Alonso Vence, Natalia, additional, Bendaña López, Ángeles, additional, Abuín Blanco, Aitor, additional, Bao Pérez, Laura, additional, Melero Valentín, Paula, additional, Sonia González Pérez, Marta, additional, Cerchione, Claudio, additional, Martinelli, Giovanni, additional, Montesinos Fernández, Pau, additional, Mateo Pérez Encinas, Manuel, additional, and Luis Bello López, José, additional

Published
2022
Full Text
View/download PDF

25. Application of IPSET‐thrombosis in 1366 Patients Prospectively Followed From the Spanish Registry of Essential Thrombocythemia.

Author

Alvarez‐Larrán, Alberto, Cuevas, Beatriz, Velez, Patricia, Noya, Soledad, Caballero‐Navarro, Gonzalo, Ferrer‐Marín, Francisca, Carbonell, Sara, Pérez‐Encinas, Manuel, Gómez‐Casares, María Teresa, Pérez‐López, Raúl, Magro, Elena, Moretó, Ana, Pastor‐Galán, Irene, Angona, Anna, Mata‐Vázquez, María Isabel, Guerrero‐Fernández, Lucía, Guerra, José María, Carreño‐Tarragona, Gonzalo, Fox, Laura, and Murillo, Ilda

Published
2023
Full Text
View/download PDF

26. Evaluation of the Stellae-123 prognostic gene expression signature in acute myeloid leukemia

Author

Mosquera Orgueira, Adrián, primary, Peleteiro Raíndo, Andrés, additional, Díaz Arias, José Ángel, additional, Antelo Rodríguez, Beatriz, additional, López Riñón, Mónica, additional, Cerchione, Claudio, additional, de la Fuente Burguera, Adolfo, additional, González Pérez, Marta Sonia, additional, Martinelli, Giovanni, additional, Montesinos Fernández, Pau, additional, and Pérez Encinas, Manuel Mateo, additional

Published
2022
Full Text
View/download PDF

27. Toxicity of Asciminib in Real Clinical Practice; Analysis of Side Effects and Cross-Intolerance with Tyrosine Kinase Inhibitors

Author

Pérez-Lamas, Lucía, Luna, Alejandro, Boque, Concepcion, Senin, María Alicia, Xicoy, Blanca, Giraldo, Pilar, Perez Lopez, Raul, Ruiz Nuño, Concepción, De las Heras, Natalia, Mora Casterá, Elvira, Garcia-Hernandez, Carmen, Segura Diaz, Adrian, Steegmann, Juan Luis, Velez Tenza, Patricia, Sanchez-Guijo, Fermin, Garcia-Noblejas Moya, Ana Maria, Juan Vera Goñi, Juan Antonio, Moreno Vega, Melania, Alvarez-Larran, Alberto, Cortes, Montse, Perez Encinas, Manuel, Serrano, Luis, Angona, Anna, Rosell, Ana, Lakhwani, Sunil, Colorado, Mercedes, Ramila, Elena, Cervero, Carlos, Cuevas, Beatriz, Villalon Blanco, Lucia, Hernandez Boluda, Juan Carlos, Paz Coll, Antonio, Gómez García de Soria, Valle, Fernández, Maria Jose, Casado, Luis Felipe, Alonso-Dominguez, Juan Manuel, Anguita Arance, Maria Magdalena, Carrascosa Mastell, Patricia, Salamanca Cuenca, Araceli, Jiménez-Velasco, Antonio, Ramírez, María José, López Esteban, Miguel, Sierra Pacho, Magdalena, Santaliestra, Marta, Alda Alvarez, Olga, de Paz, Raquel, and García Gutiérrez, Valentín

Published
2022
Full Text
View/download PDF

28. Real-World Data Analysis of the Molecular Response Kinetics within the Two First Years of the RELMC-NOVA Study in Newly Diagnosed Spanish CML-CP Patients Treated with Tirosin Kinasa Inhibitors (TKIs) in First Line

Author

Casado Montero, Luis Felipe, Garcia-Ormeña, Nuria, Perez Encinas, Manuel, Osorio-Prendes, Santiago, Ferrer Marin, Francisca, Sagüés, Miguel, Garcia-Gutiérrez, Valentín, Marco De Lucas, Fernando, Boque, Concepcion, Noya, Soledad, Gomez Casares, María Teresa, Estrada, Natalia, Goñi, Maria Angeles, Ramírez Payer, Angel, Requena, Maria Jose, Lakhwani, Sunil, Andrade Campos, Marcio Miguel, De las Heras, Natalia, Foncillas, María Ángeles, and Steegmann, Juan Luis

Published
2022
Full Text
View/download PDF

29. Supervised Machine Learning Improves Risk Stratification in Newly Diagnosed Myelodysplastic Syndromes: An Analysis of the Spanish Group of Myelodysplastic Syndromes

Author

Mosquera Orgueira, Adrian, Perez Encinas, Manuel, Diaz Varela, Nicolas A, Mora, Elvira, Díaz-Beyá, Marina, Montoro, María Julia, Pomares, Helena, Ramos, Fernando, Tormo, Mar, Jerez, Andres, Nomdedeu, Josep F, De Miguel Sanchez, Carlos, Leonor, Arenillas, Cárcel, Paula, Cedena Romero, Maria Teresa, Xicoy, Blanca, Rivero, Eugenia, del Orbe Barreto, Rafael Andres, Diez-Campelo, Maria, Benlloch, Luis E., Crucitti, Davide, and Valcárcel, David

Published
2022
Full Text
View/download PDF

30. Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory FLT3-ITD Mutation-Positive Acute Myeloid Leukemia

Author

Martínez Cuadrón, David, Serrano, Josefina, Mariz, José, Gil, Cristina, Tormo, Mar, Martínez Sánchez, Pilar, Rodríguez Arbolí, Eduardo, García Boyero, Raimundo, Rodríguez Medina, Carlos, Martínez Chamorro, Carmen, Polo, Marta, Bergua, Juan, Aguiar, Eliana, Amigo, María L., Herrera, Pilar, Alonso Domínguez, Juan Manuel, Bernal, Teresa, Espadana, Ana, Sayas, María J., Algarra, Lorenzo, Vidriales, María B., Vasconcelos, Graça, Vives, Susana, Pérez Encinas, Manuel M., López, Aurelio, Noriega Concepción, Víctor, García Fortes, María, Chillón, María C., Rodríguez Gutiérrez, Juan I., Calasanz, María J., Labrador, Jorge, López, Juan A., Boluda, Blanca, Rodríguez Veiga, Rebeca, Martínez López, Joaquín, Barragán, Eva, Sanz, Miguel A., Montesinos, Pau, Martínez Cuadrón, David, Serrano, Josefina, Mariz, José, Gil, Cristina, Tormo, Mar, Martínez Sánchez, Pilar, Rodríguez Arbolí, Eduardo, García Boyero, Raimundo, Rodríguez Medina, Carlos, Martínez Chamorro, Carmen, Polo, Marta, Bergua, Juan, Aguiar, Eliana, Amigo, María L., Herrera, Pilar, Alonso Domínguez, Juan Manuel, Bernal, Teresa, Espadana, Ana, Sayas, María J., Algarra, Lorenzo, Vidriales, María B., Vasconcelos, Graça, Vives, Susana, Pérez Encinas, Manuel M., López, Aurelio, Noriega Concepción, Víctor, García Fortes, María, Chillón, María C., Rodríguez Gutiérrez, Juan I., Calasanz, María J., Labrador, Jorge, López, Juan A., Boluda, Blanca, Rodríguez Veiga, Rebeca, Martínez López, Joaquín, Barragán, Eva, Sanz, Miguel A., and Montesinos, Pau

Abstract

This retrospective study investigated outcomes of 404 patients with relapsed/refractory (R/R) FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) acute myeloid leukemia (AML) enrolled in the PETHEMA registry, pre-approval of tyrosine kinase inhibitors. Most patients (63%) had received first-line intensive therapy with 3 + 7. Subsequently, patients received salvage with intensive therapy (n = 261), non-intensive therapy (n = 63) or supportive care only (n = 80). Active salvage therapy (i.e., intensive or non-intensive therapy) resulted in a complete remission (CR) or CR without hematological recovery (CRi) rate of 42%. More patients achieved a CR/CRi with intensive (48%) compared with non-intensive (19%) salvage therapy (p < 0.001). In the overall population, median overall survival (OS) was 5.5 months; 1- and 5-year OS rates were 25% and 7%. OS was significantly (p < 0.001) prolonged with intensive or non-intensive salvage therapy compared with supportive therapy, and in those achieving CR/CRi versus no responders. Of 280 evaluable patients, 61 (22%) had an allogeneic stem-cell transplant after they had achieved CR/CRi. In conclusion, in this large cohort study, salvage treatment approaches for patients with FLT3-ITD mutated R/R AML were heterogeneous. Median OS was poor with both non-intensive and intensive salvage therapy, with best long-term outcomes obtained in patients who achieved CR/CRi and subsequently underwent allogeneic stem-cell transplant., Centro de Investigación Biomédica en Red Cáncer (CIBERONC), Depto. de Medicina, Fac. de Medicina, TRUE, pub

Published
2022

31. Characteristics and outcomes of adult patients in the PETHEMA registry with relapsed or refractory FLT3-ITD mutation-positive acute myeloid leukemia

Author

Centro de Investigación Biomédica en Red Cáncer (España), Martínez-Cuadrón, David, Serrano, Josefina, Mariz, José, Gil, Cristina, Tormo, Mar, Martínez-Sánchez, Pilar, Rodríguez-Arbolí, Eduardo, García-Boyero, Raimundo, Rodríguez-Medina, Carlos, Martínez-Chamorro, Carmen, Polo, Marta, Bergua, Juan, Aguiar, Eliana, Amigo, María Luz, Herrera, Pilar, Alonso-Domínguez, Juan Manuel, Bernal, T., Espadana, Ana, Sayas, María-José, Algarra, Lorenzo, Vidriales, Maria Belén, Vasconcelos, Graça, Vives, Susana, Pérez-Encinas, Manuel, López, Aurelio, Noriega, Víctor, García-Fortes, María, Chillón, M. del Carmen, López, Juan A., Boluda, Blanca, Rodríguez-Veiga, Rebeca, Martínez-López, Joaquín, Barragán, Eva, Sanz, Miguel Ángel, Montesinos, Pau, Centro de Investigación Biomédica en Red Cáncer (España), Martínez-Cuadrón, David, Serrano, Josefina, Mariz, José, Gil, Cristina, Tormo, Mar, Martínez-Sánchez, Pilar, Rodríguez-Arbolí, Eduardo, García-Boyero, Raimundo, Rodríguez-Medina, Carlos, Martínez-Chamorro, Carmen, Polo, Marta, Bergua, Juan, Aguiar, Eliana, Amigo, María Luz, Herrera, Pilar, Alonso-Domínguez, Juan Manuel, Bernal, T., Espadana, Ana, Sayas, María-José, Algarra, Lorenzo, Vidriales, Maria Belén, Vasconcelos, Graça, Vives, Susana, Pérez-Encinas, Manuel, López, Aurelio, Noriega, Víctor, García-Fortes, María, Chillón, M. del Carmen, López, Juan A., Boluda, Blanca, Rodríguez-Veiga, Rebeca, Martínez-López, Joaquín, Barragán, Eva, Sanz, Miguel Ángel, and Montesinos, Pau

Abstract

This retrospective study investigated outcomes of 404 patients with relapsed/refractory (R/R) FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) acute myeloid leukemia (AML) enrolled in the PETHEMA registry, pre-approval of tyrosine kinase inhibitors. Most patients (63%) had received first-line intensive therapy with 3 + 7. Subsequently, patients received salvage with intensive therapy (n = 261), non-intensive therapy (n = 63) or supportive care only (n = 80). Active salvage therapy (i.e., intensive or non-intensive therapy) resulted in a complete remission (CR) or CR without hematological recovery (CRi) rate of 42%. More patients achieved a CR/CRi with intensive (48%) compared with non-intensive (19%) salvage therapy (p < 0.001). In the overall population, median overall survival (OS) was 5.5 months; 1- and 5-year OS rates were 25% and 7%. OS was significantly (p < 0.001) prolonged with intensive or non-intensive salvage therapy compared with supportive therapy, and in those achieving CR/CRi versus no responders. Of 280 evaluable patients, 61 (22%) had an allogeneic stem-cell transplant after they had achieved CR/CRi. In conclusion, in this large cohort study, salvage treatment approaches for patients with FLT3-ITD mutated R/R AML were heterogeneous. Median OS was poor with both non-intensive and intensive salvage therapy, with best long-term outcomes obtained in patients who achieved CR/CRi and subsequently underwent allogeneic stem-cell transplant.

Published
2022

32. Azacitidine vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the PETHEMA Registry

Author

Labrador, Jorge, Martínez-Cuadrón, David, Fuente, Adolfo de la, Rodríguez-Veiga, Rebeca, Serrano, Josefina, Tormo, Mar, Rodríguez-Arbolí, Eduardo, Ramos, Fernando, Bernal, Teresa, López-Pavía, María, Trigo, Fernanda, Martínez-Sánchez, Pilar, Rodríguez-Gutiérrez, Juan I., Rodríguez-Medina, Carlos, Gil, Cristina, García-Belmonte, Daniel, Vives, Susana, Foncillas, María-Ángeles, Pérez-Encinas, Manuel, Novo Amado, A., Recio, Isabel, Rodríguez-Macías, Gabriela, Bergua, Juan, Noriega, Víctor, Lavilla, Esperanza, Roldán-Pérez, Alicia, Sanz, Miguel Ángel, Montesinos, Pau, Labrador, Jorge, Martínez-Cuadrón, David, Fuente, Adolfo de la, Rodríguez-Veiga, Rebeca, Serrano, Josefina, Tormo, Mar, Rodríguez-Arbolí, Eduardo, Ramos, Fernando, Bernal, Teresa, López-Pavía, María, Trigo, Fernanda, Martínez-Sánchez, Pilar, Rodríguez-Gutiérrez, Juan I., Rodríguez-Medina, Carlos, Gil, Cristina, García-Belmonte, Daniel, Vives, Susana, Foncillas, María-Ángeles, Pérez-Encinas, Manuel, Novo Amado, A., Recio, Isabel, Rodríguez-Macías, Gabriela, Bergua, Juan, Noriega, Víctor, Lavilla, Esperanza, Roldán-Pérez, Alicia, Sanz, Miguel Ángel, and Montesinos, Pau

Abstract

[Simple Summary] The use of azacitidine (AZA) and decitabine (DEC) have allowed more elderly acute myeloid leukemia (AML) patients to be treated. However, scarcely any direct comparative data exist between both drugs. This study shows no significant differences in response rates or overall survival (OS) between upfront AZA and DEC treatment in a large retrospective with long-term follow-up cohort of AML patients. However, we identified for the first time the baseline characteristics of patients benefitting from AZA vs. DEC in terms of responses, 120-day mortality and OS. We also show differences in salvage treatment patterns and outcomes after failure to both hypomethylating agents in a real-life setting. Taken together, these findings could help to select the most appropriate hypomethylating agent in monotherapy., The hypomethylating agents, decitabine (DEC) and azacitidine (AZA), allowed more elderly acute myeloid leukemia (AML) patients to be treated. However, there are little direct comparative data on AZA and DEC. This multicenter retrospective study compared the outcomes of AZA and DEC in terms of response and overall survival (OS). Potential predictors associated with response and OS were also evaluated. A total of 626 AML patients were included (487 treated with AZA and 139 with DEC). Response rates were similar in both groups: CR was 18% with AZA vs. 23% with DEC (p = 0.20), CR/CRi was 20.5% vs. 25% (p = 0.27) and ORR was 32% vs. 39.5% (p = 0.12), respectively. Patients with leukocytes < 10 × 109/L, bone marrow blasts < 50% and ECOG ≥ 2 had higher ORR with DEC than with AZA. OS was similar in both groups: 10.4 months (95% CI: 9.2–11.7) vs. 8.8 months (95% CI: 6.7–11.0, p = 0.455), for AZA and DEC, respectively. Age (≥80 years), leukocytes (≥ 10 × 109/L), platelet count (<20 × 109/L) and eGFR (≥45 mL/min/1.73 m2) were associated with higher OS with AZA compared to DEC. In conclusion, we found no differences in response and OS rates in AML patients treated with AZA or DEC.

Published
2022

33. Oral anticoagulation to prevent thrombosis recurrence in polycythemia vera and essential thrombocythemia

Author

Hernández-Boluda, Juan-Carlos, Arellano-Rodrigo, Eduardo, Cervantes, Francisco, Alvarez-Larrán, Alberto, Gómez, Montse, Barba, Pere, Mata, María-Isabel, González-Porras, José-Ramón, Ferrer-Marín, Francisca, García-Gutiérrez, Valentín, Magro, Elena, Moreno, Melania, Kerguelen, Ana, Pérez-Encinas, Manuel, Estrada, Natàlia, Ayala, Rosa, Besses, Carles, Pereira, Arturo, and on behalf of the Grupo Español de Enfermedades Mieloproliferativas Filadelfia Negativas (GEMFIN)

Published
2015
Full Text
View/download PDF

34. Use of Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia: The PETHEMA Registry Experience

Author

Labrador, Jorge, primary, Saiz-Rodríguez, Miriam, additional, de Miguel, Dunia, additional, de Laiglesia, Almudena, additional, Rodríguez-Medina, Carlos, additional, Vidriales, María Belén, additional, Pérez-Encinas, Manuel, additional, Sánchez-Sánchez, María José, additional, Cuello, Rebeca, additional, Roldán-Pérez, Alicia, additional, Vives, Susana, additional, Benzo-Callejo, Gonzalo, additional, Colorado, Mercedes, additional, García-Fortes, María, additional, Sayas, María José, additional, Olivier, Carmen, additional, Recio, Isabel, additional, Conde-Royo, Diego, additional, Bienert-García, Álvaro, additional, Vahi, María, additional, Muñoz-García, Carmen, additional, Seri-Merino, Cristina, additional, Tormo, Mar, additional, Vall-llovera, Ferran, additional, Foncillas, María-Ángeles, additional, Martínez-Cuadrón, David, additional, Sanz, Miguel Ángel, additional, and Montesinos, Pau, additional

Published
2022
Full Text
View/download PDF

35. Prognostic Stratification of Diffuse Large B-cell Lymphoma Using Clinico-genomic Models: Validation and Improvement of the LymForest-25 Model

Author

Mosquera Orgueira, Adrián, primary, Díaz Arías, Jose Ángel, additional, Cid López, Miguel, additional, Peleteiro Raíndo, Andrés, additional, López García, Alberto, additional, Abal García, Rosanna, additional, González Pérez, Marta Sonia, additional, Antelo Rodríguez, Beatriz, additional, Aliste Santos, Carlos, additional, Pérez Encinas, Manuel Mateo, additional, Fraga Rodríguez, Máximo Francisco, additional, and Bello López, José Luis, additional

Published
2022
Full Text
View/download PDF

36. Real-world analysis of main clinical outcomes in patients with polycythemia vera treated with ruxolitinib or best available therapy after developing resistance/intolerance to hydroxyurea

Author

Alvarez-Larrán, Alberto, Garrote, Marta, Ferrer-Marín, Francisca, Pérez-Encinas, Manuel, Mata-Vazquez, M Isabel, Bellosillo, Beatriz, Arellano-Rodrigo, Eduardo, Gómez, Montse, García, Regina, García-Gutiérrez, Valentín, Gasior, Mercedes, Cuevas, Beatriz, Angona, Anna, Gómez-Casares, María Teresa, Martínez, Clara M, Magro, Elena, Ayala, Rosa, Del Orbe-Barreto, Rafael, Pérez-López, Raúl, Fox, Maria Laura, Raya, José-María, Guerrero, Lucía, García-Hernández, Carmen, Caballero, Gonzalo, Murillo, Ilda, Xicoy, Blanca, Ramírez, M José, Carreño-Tarragona, Gonzalo, Hernández-Boluda, Juan Carlos, Pereira, Arturo, MPN Spanish Group (Grupo Español de Enfermedades Mieloproliferativas Filadelfia Negativas), Institut Català de la Salut, [Alvarez-Larrán A, Garrote M] Hospital Clínic, Institut d’Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain. [Ferrer-Marín F] Hospital Morales Messeguer, Universidad Católica San Antonio de Murcia, Murcia, Centro de Investigación Biomédica en Red de Enfermedades Raras, Murcia, Spain. [Pérez-Encinas M] Hospital Clínico Universitario, Santiago de Compostela, Spain. [Mata-Vazquez MI] Hospital Costa del Sol, Marbella, Spain. [Bellosillo B] Hospital del Mar, Barcelona, Spain. [Fox ML] Vall d’Hebron Hospital Universitari, Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus

Subjects
Cancer Research, Medicaments antineoplàstics - Ús terapèutic, Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores], Myelofibrosis, Hemorrhage, Other subheadings::Other subheadings::/drug therapy [Other subheadings], Otros calificadores::Otros calificadores::/efectos adversos [Otros calificadores], Myeloproliferative neoplasms, neoplasias::neoplasias por localización::neoplasias hematológicas::neoplasias de la médula ósea::policitemia vera [ENFERMEDADES], Nitriles, Other subheadings::Other subheadings::/adverse effects [Other subheadings], Humans, Hydroxyurea, Retrospective Studies, Neoplasms::Neoplasms by Site::Hematologic Neoplasms::Bone Marrow Neoplasms::Polycythemia Vera [DISEASES], acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos [COMPUESTOS QUÍMICOS Y DROGAS], diagnóstico::pronóstico::resultado del tratamiento [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Neoplasms, Second Primary, Thrombosis, Diagnosis::Prognosis::Treatment Outcome [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Polycythemia vera, Leukemia, Myeloid, Acute, Pyrimidines, Ruxolitinib, Oncology, Policitèmia - Tractament, Primary Myelofibrosis, Avaluació de resultats (Assistència sanitària), Pyrazoles, Therapy, Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents [CHEMICALS AND DRUGS]
Abstract

Altres ajuts: Novartis. Background: Ruxolitinib is approved for patients with polycythemia vera (PV) who are resistant/intolerant to hydroxyurea, but its impact on preventing thrombosis or disease-progression is unknown. Methods: A retrospective, real-world analysis was performed on the outcomes of 377 patients with resistance/intolerance to hydroxyurea from the Spanish Registry of Polycythemia Vera according to subsequent treatment with ruxolitinib (n = 105) or the best available therapy (BAT; n = 272). Survival probabilities and rates of thrombosis, hemorrhage, acute myeloid leukemia, myelofibrosis, and second primary cancers were calculated according to treatment. To minimize biases in treatment allocation, all results were adjusted by a propensity score for receiving ruxolitinib or BAT. Results: Patients receiving ruxolitinib had a significantly lower rate of arterial thrombosis than those on BAT (0.4% vs 2.3% per year; P =.03), and this persisted as a trend after adjustment for the propensity to have received the drug (incidence rate ratio, 0.18; 95% confidence interval, 0.02-1.3; P =.09). There were no significant differences in the rates of venous thrombosis (0.8% and 1.1% for ruxolitinib and BAT, respectively; P =.7) and major bleeding (0.8% and 0.9%, respectively; P =.9). Ruxolitinib exposure was not associated with a higher rate of second primary cancers, including all types of neoplasia, noncutaneous cancers, and nonmelanoma skin cancers. After a median follow-up of 3.5 years, there were no differences in survival or progression to acute leukemia or myelofibrosis between the 2 groups. Conclusions: The results suggest that ruxolitinib treatment for PV patients with resistance/intolerance to hydroxyurea may reduce the incidence of arterial thrombosis. Lay Summary: Ruxolitinib is better than other available therapies in achieving hematocrit control and symptom relief in patients with polycythemia vera who are resistant/intolerant to hydroxyurea, but we still do not know whether ruxolitinib provides an additional benefit in preventing thrombosis or disease progression. We retrospectively studied the outcomes of 377 patients with resistance/intolerance to hydroxyurea from the Spanish Registry of Polycythemia Vera according to whether they subsequently received ruxolitinib (n = 105) or the best available therapy (n = 272). Our findings suggest that ruxolitinib could reduce the incidence of arterial thrombosis, but a disease-modifying effect could not be demonstrated for ruxolitinib in this patient population.

Published
2022

37. Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens

Author

Montesinos, Pau, Rayón, Chelo, Vellenga, Edo, Brunet, Salut, González, José, González, Marcos, Holowiecka, Aleksandra, Esteve, Jordi, Bergua, Juan, González, José D., Rivas, Concha, Tormo, Mar, Rubio, Vicente, Bueno, Javier, Manso, Félix, Milone, Gustavo, de la Serna, Javier, Pérez, Inmaculada, Pérez-Encinas, Manuel, Krsnik, Isabel, Ribera, Josep M., Escoda, Lourdes, Lowenberg, Bob, and Sanz, Miguel A.

Published
2011
Full Text
View/download PDF

38. Personally Tailored Survival Prediction of Patients With Follicular Lymphoma Using Machine Learning Transcriptome-Based Models

Author

Mosquera Orgueira, Adrián, primary, Cid López, Miguel, additional, Peleteiro Raíndo, Andrés, additional, Abuín Blanco, Aitor, additional, Díaz Arias, Jose Ángel, additional, González Pérez, Marta Sonia, additional, Antelo Rodríguez, Beatriz, additional, Bao Pérez, Laura, additional, Ferreiro Ferro, Roi, additional, Aliste Santos, Carlos, additional, Pérez Encinas, Manuel Mateo, additional, Fraga Rodríguez, Máximo Francisco, additional, Cerchione, Claudio, additional, Mozas, Pablo, additional, and Bello López, José Luis, additional

Published
2022
Full Text
View/download PDF

39. Frequency and prognostic value of resistance/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera

Author

Alvarez-Larrán, Alberto, Kerguelen, Ana, Hernández-Boluda, Juan C., Pérez-Encinas, Manuel, Ferrer-Marín, Francisca, Bárez, Abelardo, Martínez-López, Joaquín, Cuevas, Beatriz, Mata, Isabel M., García-Gutiérrez, Valentín, Aragües, Pilar, Montesdeoca, Sara, Burgaleta, Carmen, Caballero, Gonzalo, Hernández-Rivas, Angel J., Durán, Antonia M., Gómez-Casares, Teresa M., and Besses, Carles

Published
2016
Full Text
View/download PDF

40. Venetoclax Therapy in a Heavily Treated Cohort of Patients with Relapsed or Refractory Acute Myeloid Leukemia: Update of the Pethema Registry Experience

Author

Labrador, Jorge, primary, Saiz-Rodríguez, Miriam, additional, De Miguel, Maria Dunia, additional, De Laiglesia, Almudena, additional, Rodriguez, Carlos, additional, Belén Vidriales, María, additional, Pérez-Encinas, Manuel, additional, Sanchez, Maria Jose, additional, Cuello, Rebeca, additional, Roldán Pérez, Alicia, additional, Vives, Susana, additional, Benzo Callejo, Gonzalo, additional, Araujo, Mercedes Colorado, additional, García-Fortes, María, additional, Sayas, Maria Jose, additional, Olivier, Carmen, additional, Recio, Isabel, additional, Conde, Diego, additional, Bienert Garcia, Alvaro, additional, Vahi, Maria, additional, Muñoz García, Carmen, additional, Seri, Cristina, additional, Tormo, Mar, additional, Vall-llovera, Ferran, additional, Foncillas, Maria Angeles, additional, Martínez-Cuadrón, David, additional, Sanz, Miguel A., additional, and Montesinos, Pau, additional

Published
2021
Full Text
View/download PDF

41. Efficacy and Safety of Treatment Venetoclax Monotherapy or Combined with Rituximab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) in the Real -World Setting in Spain: The Venares Study

Author

Baltasar, Patricia, primary, Terol, María José, additional, Marquet Palomanes, Juan, additional, Ramírez Payer, Angel, additional, Moreno, Carol, additional, Osorio, Santiago, additional, De la Cruz, Fátima, additional, Garcia-Marco, Jose A., additional, Ortiz, Macarena, additional, Ríos Herranz, Eduardo, additional, Magnano, Laura, additional, Iraheta, Sandra, additional, Puerta, Jose Manuel, additional, de la Serna, Javier, additional, Smucler Simonovich, Alicia, additional, Arguiñano, Jose Maria, additional, Loscertales, Javier, additional, Muiña, Begoña, additional, Fernandez, Ruben, additional, García, Tomas, additional, Márquez, José A., additional, Muntañola Prat, Ana, additional, Pérez Persona, Ernesto, additional, Yáñez, Lucrecia, additional, Pérez-Encinas, Manuel, additional, González Díaz, Marcos, additional, Caballero, Gonzalo, additional, Andreu, María Angeles, additional, Andreu, Rafael, additional, Ruiz-Zorrilla, Ana, additional, Moreno, Diana, additional, and Ferrà, Christelle, additional

Published
2021
Full Text
View/download PDF

42. Predictors of thrombosis and bleeding in 1613 myelofibrosis patients from the Spanish Registry of Myelofibrosis.

Author

Hernández‐Boluda, Juan‐Carlos, Pastor‐Galán, Irene, Arellano‐Rodrigo, Eduardo, Raya, José‐María, Pérez‐Encinas, Manuel, Ayala, Rosa, Ferrer‐Marín, Francisca, Velez, Patricia, Mora, Elvira, Fox, María‐Laura, Hernández‐Rivas, Jesús‐María, Xicoy, Blanca, Mata‐Vázquez, María‐Isabel, García‐Fortes, María, Pérez‐López, Raúl, Angona, Anna, Cuevas, Beatriz, Senín, Alicia, Ramírez, María‐José, and Ramírez‐Payer, Angel

Subjects
MYELOFIBROSIS, THROMBOSIS, VENOUS thrombosis, HEMORRHAGE, ANTICOAGULANTS
Abstract

Summary: Available data have proved insufficient to develop consensus recommendations on the prevention of thrombosis and bleeding in myelofibrosis (MF). We evaluated the incidence and risk factors of vascular complications in 1613 patients from the Spanish Myelofibrosis Registry. Over a total of 6981 patient‐years at risk, 6.4% of the study population had at least one thrombotic event after MF diagnosis, amounting to an incidence rate of 1.65 per 100 patient‐years. Prior history of thrombosis, the JAK2 mutation, and the intermediate‐2/high‐risk International Prognostic Scoring System (IPSS) categories conferred an increased thrombotic risk after adjustment for the risk‐modifying effect of anti‐thrombotic and cytoreductive treatments. History of thrombosis and the JAK2 mutation allowed us to pinpoint a group of patients at higher risk of early thrombosis. No decreased incidence of thrombosis was observed while patients were on anti‐thrombotic or cytoreductive treatment. An increased risk of venous thrombosis was found during treatment with immunomodulatory agents. A total of 5.3% of patients had at least one episode of major bleeding, resulting in an incidence rate of 1.5 events per 100 patient‐years. Patients in the intermediate‐2/high‐risk IPSS categories treated with anti‐coagulants had an almost sevenfold increased risk of major bleeding. These findings should prove useful for guiding decision‐making in clinical practice. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

43. Safety of FLT3 inhibitors in patients with acute myeloid leukemia

Author

Cerchione, Claudio, primary, Peleteiro Raíndo, Andrés, additional, Mosquera Orgueira, Adrián, additional, Mosquera Torre, Alicia, additional, Bao Pérez, Laura, additional, Marconi, Giovanni, additional, Isidori, Alessandro, additional, Pérez Encinas, Manuel Mateo, additional, and Martinelli, Giovanni, additional

Published
2021
Full Text
View/download PDF

44. Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice

Author

Garcia-Gutierrez, Valentin, Luna, Alejandro, Alonso-Dominguez, Juan M., Estrada Barreras, Natalia, Boque, Concepcion, Xicoy, Blanca, Giraldo, Pilar, Angona, Anna, Álvarez Larrán, Alberto, Sanchez-Guijo, Fermin, Ramírez, María José, Mora, Elvira, Vélez, Patricia, Rosell, Ana, Colorado Araujo, Mercedes, Cuevas, Beatriz, Sagüés, Miguel, Cortés, Montserrat, Pérez Encinas, Manuel, Casado Montero, Luis Felipe, Moreno Vega, Melania, Serrano, Luis, Gomez, Valle, Garcia-Hernandez, Carmen, Lakhwani, Sunil, Paz Coll, Antonio, De Paz, Raquel, Suarez-Varela, Sara, Fernandez-Ruiz, Andrés, Perez Lopez, Raul, Ortiz-Fernández, Almudena, Jiménez-Velasco, Antonio, Steegmann-Olmedillas, Juan Luis, Hernandez-Boluda, Juan Carlos, Universitat Autònoma de Barcelona, [Garcia-Gutiérrez V, Luna A] Hematology, Hospital Universitario Ramón y Cajal. IRYCIS, Madrid, Spain. [Alonso-Dominguez JM] Hospital Universitario Fundación Jiménez Díaz, Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD), UAM, Madrid, Spain. [Estrada N, Xicoy B] Institut Català d’Oncologia, Hospital Germans Trias i Pujol, Josep Carreras Leukemia Research Institute, Universitat Autònoma de Barcelona, Badalona, Spain. [Boque C] Institut Català d’Oncologia – L’Hospitalet de Llobregat, L’Hospitalet de Llobregat, Spain. [Cortes M] Hospital General de Granollers, Granollers, Spain, and Departament de Salut

Subjects
Adult, Male, Niacinamide, medicine.medical_specialty, Heterocyclic Compounds::Acids, Heterocyclic::Nicotinic Acids::Niacinamide [CHEMICALS AND DRUGS], MEDLINE, Fusion Proteins, bcr-abl, Drug development, Hemic and Lymphatic Diseases::Hematologic Diseases::Bone Marrow Diseases::Myeloproliferative Disorders::Leukemia, Myelogenous, Chronic, BCR-ABL Positive [DISEASES], lcsh:RC254-282, Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Enzyme Inhibitors::Protein Kinase Inhibitors [CHEMICALS AND DRUGS], Young Adult, Text mining, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, hemic and lymphatic diseases, Correspondence, compuestos heterocíclicos::ácidos heterocíclicos::ácidos nicotínicos::niacinamida [COMPUESTOS QUÍMICOS Y DROGAS], Medicine, In real life, Humans, Intensive care medicine, Protein Kinase Inhibitors, Aged, Aged, 80 and over, Leucèmia mieloide crònica - Tractament, business.industry, acciones y usos químicos::acciones farmacológicas::mecanismos moleculares de acción farmacológica::inhibidores enzimáticos::inhibidores de proteínas cinasas [COMPUESTOS QUÍMICOS Y DROGAS], Myeloid leukemia, Hematology, Middle Aged, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Tiroxina - Inhibidors, Clinical Practice, Treatment Outcome, Oncology, Molecularly targeted therapy, Proteïna quinasa CK2, Pyrazoles, Female, enfermedades hematológicas y linfáticas::enfermedades hematológicas::enfermedades de la médula ósea::trastornos mieloproliferativos::leucemia mielogenosa crónica BCR-ABL positiva [ENFERMEDADES], business
Abstract

Chronic myeloid leukemia; Asciminib; Treatment Leucemia mieloide crónica; Asciminib; Tratamiento Leucèmia mieloide crònica; Asciminib; Tractament Despite the excellent overall survival (OS) of chronic myeloid leukemia (CML) patients, a significant proportion will fail currently available tyrosine-kinase inhibitors (TKIs) due to resistance or intolerance. Intolerant patients are usually managed successfully with alternative second-generation tyrosine-kinase inhibitors (2GTKIs). However, more than half of the patients will eventually discontinue second-line treatment due to loss of response or toxicity. Ponatinib is an effective drug in the setting of resistance to 2GTKIs, however with life-threatening side effects and varying responses. Asciminib is a first-in-class STAMP (Specifically Targeting the ABL Myristoyl Pocket) inhibitor that potently and specifically inhibits BCR-ABL1 via binding to a pocket distinct from the ATP binding site of the kinase. Asciminib has the potential to overcome resistance to prior TKIs, and also offers the possibility of dual inhibition of BCR-ABL1 in combination with ATP-binding TKIs. Asciminib has been evaluated in a phase I study in patients with Ph-positive leukemia failing prior TKIs, with promising results. Our aim is to share the first data on the use of asciminib in CML patients in clinical practice, allowed by Novartis under a managed-access program (MAP).

Published
2021

45. Detection of new drivers of frequent B-cell lymphoid neoplasms using an integrated analysis of whole genomes

Author

Universidade de Santiago de Compostela. Departamento de Ciencias Forenses, Anatomía Patolóxica, Xinecoloxía e Obstetricia, e Pediatría, Universidade de Santiago de Compostela. Departamento de Psiquiatría, Radioloxía, Saúde Pública, Enfermaría e Medicina, Mosquera Orgueira, Adrián, Ferreiro Ferro, Roi, Díaz Arias, José Ángel, Aliste Santos, Carlos, Antelo Rodríguez, Beatriz, Bao Pérez, Laura, Alonso Vence, Natalia, Bendaña López, María Ángeles, Abuin Blanco, Aitor, Melero Valentín, Paula, Peleteiro Raíndo, Andrés, Cid López, Miguel, Pérez Encinas, Manuel Mateo, González Pérez, Marta Sonia, Fraga Rodríguez, Máximo Francisco, Bello López, José Luis, Universidade de Santiago de Compostela. Departamento de Ciencias Forenses, Anatomía Patolóxica, Xinecoloxía e Obstetricia, e Pediatría, Universidade de Santiago de Compostela. Departamento de Psiquiatría, Radioloxía, Saúde Pública, Enfermaría e Medicina, Mosquera Orgueira, Adrián, Ferreiro Ferro, Roi, Díaz Arias, José Ángel, Aliste Santos, Carlos, Antelo Rodríguez, Beatriz, Bao Pérez, Laura, Alonso Vence, Natalia, Bendaña López, María Ángeles, Abuin Blanco, Aitor, Melero Valentín, Paula, Peleteiro Raíndo, Andrés, Cid López, Miguel, Pérez Encinas, Manuel Mateo, González Pérez, Marta Sonia, Fraga Rodríguez, Máximo Francisco, and Bello López, José Luis

Abstract

B-cell lymphoproliferative disorders exhibit a diverse spectrum of diagnostic entities with heterogeneous behaviour. Multiple efforts have focused on the determination of the genomic drivers of B-cell lymphoma subtypes. In the meantime, the aggregation of diverse tumors in pan-cancer genomic studies has become a useful tool to detect new driver genes, while enabling the comparison of mutational patterns across tumors. Here we present an integrated analysis of 354 B-cell lymphoid disorders. 112 recurrently mutated genes were discovered, of which KMT2D, CREBBP, IGLL5 and BCL2 were the most frequent, and 31 genes were putative new drivers. Mutations in CREBBP, TNFRSF14 and KMT2D predominated in follicular lymphoma, whereas those in BTG2, HTA-A and PIM1 were more frequent in diffuse large B-cell lymphoma. Additionally, we discovered 31 significantly mutated protein networks, reinforcing the role of genes such as CREBBP, EEF1A1, STAT6, GNA13 and TP53, but also pointing towards a myriad of infrequent players in lymphomagenesis. Finally, we report aberrant expression of oncogenes and tumor suppressors associated with novel noncoding mutations (DTX1 and S1PR2), and new recurrent copy number aberrations affecting immune check-point regulators (CD83, PVR) and B-cell specific genes (TNFRSF13C). Our analysis expands the number of mutational drivers of B-cell lymphoid neoplasms, and identifies several differential somatic events between disease subtypes

Published
2021

46. A phase 3 trial of azacitidine versus a semi-intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia

Author

Instituto de Salud Carlos III, Celgene, Vives, Susana, Martínez-Cuadrón, David, Bergua, Juan, Algarra, Lorenzo, Tormo, Mar, Martínez-Sánchez, María Pilar, Serrano-López, Josefina, Herrera, Pilar, Ramos, Fernando, Salamero, Olga, Lavilla, Esperanza, López-Lorenzo, José L., Gil, Cristina, Vidriales, Maria Belén, Falantes-González, José Francisco, Serrano, Alfons, Labrador, Jorge, Sayas, María-José, Foncillas, María-Ángeles, Amador Barciela, María L., Olave, María-Teresa, Colorado, Mercedes, Gascón, Adriana, Fernández, María Á., Simiele, Adriana, Pérez-Encinas, Manuel, Rodríguez-Veiga, Rebeca, García, Olga, Martínez-López, Joaquín, Barragán, Eva, Paiva, Bruno, Sanz, Miguel Ángel, Montesinos, Pau, Instituto de Salud Carlos III, Celgene, Vives, Susana, Martínez-Cuadrón, David, Bergua, Juan, Algarra, Lorenzo, Tormo, Mar, Martínez-Sánchez, María Pilar, Serrano-López, Josefina, Herrera, Pilar, Ramos, Fernando, Salamero, Olga, Lavilla, Esperanza, López-Lorenzo, José L., Gil, Cristina, Vidriales, Maria Belén, Falantes-González, José Francisco, Serrano, Alfons, Labrador, Jorge, Sayas, María-José, Foncillas, María-Ángeles, Amador Barciela, María L., Olave, María-Teresa, Colorado, Mercedes, Gascón, Adriana, Fernández, María Á., Simiele, Adriana, Pérez-Encinas, Manuel, Rodríguez-Veiga, Rebeca, García, Olga, Martínez-López, Joaquín, Barragán, Eva, Paiva, Bruno, Sanz, Miguel Ángel, and Montesinos, Pau

Abstract

[Background] Options to treat elderly patients (≥65 years old) newly diagnosed with acute myeloid leukemia (AML) include intensive and attenuated chemotherapy, hypomethylating agents with or without venetoclax, and supportive care. This multicenter, randomized, open-label, phase 3 trial was designed to assess the efficacy and safety of a fludarabine, cytarabine, and filgrastim (FLUGA) regimen in comparison with azacitidine (AZA)., [Methods] Patients (n = 283) were randomized 1:1 to FLUGA (n = 141) or AZA (n = 142). Response was evaluated after cycles 1, 3, 6, and 9. Measurable residual disease (MRD) was assessed after cycle 9. When MRD was ≥0.01%, patients continued with the treatment until relapse or progressive disease. Patients with MRD < 0.01% suspended treatment to enter the follow-up phase. [Results] The complete remission (CR) rate after 3 cycles was significantly better in the FLUGA arm (18% vs 9%; P = .04), but the CR/CR with incomplete recovery rate at 9 months was similar (33% vs 29%; P = .41). There were no significant differences between arms in early mortality at 30 or 60 days. Hematologic toxicities were more frequent with FLUGA, especially during induction. The 1-year overall survival (OS) rate and the median OS were superior with AZA versus FLUGA: 47% versus 27% and 9.8 months (95% confidence interval [CI], 5.6-14 months) versus 4.1 months (95% CI, 2.7-5.5 months; P = .005), respectively. The median event-free survival was 4.9 months (95% CI, 2.8-7 months) with AZA and 3 months (95% CI, 2.5-3.5 months) with FLUGA (P = .001). [Conclusions] FLUGA achieved more remissions after 3 cycles, but the 1-year OS rate was superior with AZA. However, long-term outcomes were disappointing in both arms (3-year OS rate, 10% vs 5%). This study supports the use of an AZA backbone for future combinations in elderly patients with AML.

Published
2021

47. Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia

Author

Centro de Investigación Biomédica en Red Cáncer (España), Instituto de Salud Carlos III, Junta de Castilla y León, Universidad de Navarra, Cancer Research UK, Fondazione Italiana per la Ricerca sul Cancro, Asociación Española Contra el Cáncer, Paiva, Bruno, Vidriales, Maria Belén, Sempere, Amparo, Tarín, Fabián, Colado, Enrique, Benavente, Celina, Cedena, Maria-Teresa, Sánchez, Joaquín, Caballero-Velázquez, Teresa, Cordón, Lourdes, Garcés, Juan José, Simoes, Catia, Martínez-Cuadrón, David, Bernal, T., Botella, Carmen, Grille, Sofía, Serrano-López, Josefina, Rodríguez-Medina, Carlos, Algarra, Lorenzo, Alonso-Domínguez, Juan Manuel, Amigo, María Luz, Barrios, Manuel, García-Boyero, Raimundo, Colorado, Mercedes, Pérez de Oteyza, Jaime, Pérez-Encinas, Manuel, Costilla-Barriga, Lisette, Sayas, María-José, Pérez, Olga, González, Marcos, Pérez-Simón, José A., Martínez-López, Joaquín, Sossa, Claudia, Orfao, Alberto, Miguel, Jesus F. San, Sanz, Miguel Ángel, Montesinos, Pau, Centro de Investigación Biomédica en Red Cáncer (España), Instituto de Salud Carlos III, Junta de Castilla y León, Universidad de Navarra, Cancer Research UK, Fondazione Italiana per la Ricerca sul Cancro, Asociación Española Contra el Cáncer, Paiva, Bruno, Vidriales, Maria Belén, Sempere, Amparo, Tarín, Fabián, Colado, Enrique, Benavente, Celina, Cedena, Maria-Teresa, Sánchez, Joaquín, Caballero-Velázquez, Teresa, Cordón, Lourdes, Garcés, Juan José, Simoes, Catia, Martínez-Cuadrón, David, Bernal, T., Botella, Carmen, Grille, Sofía, Serrano-López, Josefina, Rodríguez-Medina, Carlos, Algarra, Lorenzo, Alonso-Domínguez, Juan Manuel, Amigo, María Luz, Barrios, Manuel, García-Boyero, Raimundo, Colorado, Mercedes, Pérez de Oteyza, Jaime, Pérez-Encinas, Manuel, Costilla-Barriga, Lisette, Sayas, María-José, Pérez, Olga, González, Marcos, Pérez-Simón, José A., Martínez-López, Joaquín, Sossa, Claudia, Orfao, Alberto, Miguel, Jesus F. San, Sanz, Miguel Ángel, and Montesinos, Pau

Abstract

The role of decentralized assessment of measurable residual disease (MRD) for risk stratification in acute myeloid leukemia (AML) remains largely unknown, and so it does which methodological aspects are critical to empower the evaluation of MRD with prognostic significance, particularly if using multiparameter flow cytometry (MFC). We analyzed 1076 AML patients in first remission after induction chemotherapy, in whom MRD was evaluated by MFC in local laboratories of 60 Hospitals participating in the PETHEMA registry. We also conducted a survey on technical aspects of MRD testing to determine the impact of methodological heterogeneity in the prognostic value of MFC. Our results confirmed the recommended cutoff of 0.1% to discriminate patients with significantly different cumulative-incidence of relapse (-CIR- HR:0.71, P < 0.001) and overall survival (HR: 0.73, P = 0.001), but uncovered the limited prognostic value of MFC based MRD in multivariate and recursive partitioning models including other clinical, genetic and treatment related factors. Virtually all aspects related with methodological, interpretation, and reporting of MFC based MRD testing impacted in its ability to discriminate patients with different CIR. Thus, this study demonstrated that “real-world” assessment of MRD using MFC is prognostic in patients at first remission, and urges greater standardization for improved risk-stratification toward clinical decisions in AML.

Published
2021

48. Clinical and Molecular Characterization of Triple-Negative Essential Thrombocythemia: Data from the Prospective Spanish Registry of Essential Thrombocythemia

Author

Gil-Manso, Rodrigo, Carreño, Gonzalo, Hernandez Boluda, Juan Carlos, Perez Lopez, Raul, Gómez-Casares, Maria Teresa, Ferrer Marin, Francisca, Arellano-Rodrigo, Eduardo, Angona, Anna, García Gutiérrez, Valentín, Noya, Maria Soledad, Senin, María Alicia, Magro, Elena, Pastor, Irene, Mata, María Isabel, Cuevas, Beatriz, Mora, Elvira, Martinez, Cristina, Alonso-Dominguez, Juan M., Pérez-Encinas, Manuel, Caballero Navarro, Gonzalo, Cortes Vázquez, Miguel A., del Río, Carmen, Martinez Lopez, Joaquin, Ayala, Rosa, and Alvarez-Larran, Alberto

Published
2023
Full Text
View/download PDF

50. Exploring Potential Molecular Mechanisms of Drug Response in FLT3-ITD Negative AML Patients Treated with Quizartinib Vs Placebo Plus Standard Chemotherapy in the Quiwi Trial

Author

Mosquera Orgueira, Adrian, Perez Encinas, Manuel, Diaz Arias, Jose Angel, Rodriguez Veiga, Rebeca, Bergua Burgues, Juan Miguel, Algarra, Lorenzo, Botella, Carmen, Perez Simon, Jose Antonio, Bernal, Teresa, Tormo, Mar, Calbacho, Maria, Salamero, Olga, Serrano, Josefina, Noriega, Victor, Lopez Lopez, Juan Antonio, Vives, Susana, Colorado, Mercedes, Lopez Lorenzo, Jose Luis, Vidriales Vicente, Maria, Garcia Boyero, Raimundo, Olave Rubio, Maria Teresa, Herrera Puente, Pilar, Arce, Olga, Barrios Garcia, Manuel, Sayas Lloris, Maria Jose, Polo, Marta, Gomez Roncero, Maria Isabel, Barragan, Eva, Ayala, Rosa, Chillon, Carmen, Calasanz, Maria Jose, Boluda, Blanca, Peleteiro Raindo, Andres, Amigo, Raquel, Labrador, Jorge, Martinez Cuadron, David, and Montesinos, Pau

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results